Are ICE’s GPU Compute and Crypto-Linked Futures Expansions Altering The Investment Case For Intercontinental Exchange (ICE)?

Intercontinental Exchange, Inc.

Intercontinental Exchange, Inc.

ICE

0.00

  • In May 2026, Intercontinental Exchange, Inc. (ICE) expanded its rulebook for regulatory compliance and announced new Ornn-linked GPU compute futures, broader VaR-based margining for ERCOT power markets, and a crypto-partnered oil perpetual futures suite alongside record futures and options open interest.
  • Together, these moves highlight ICE’s push to standardize pricing and risk management across emerging assets like GPU compute while deepening its role in traditional energy and multicurrency derivatives.
  • We’ll now examine how ICE’s planned GPU compute futures launch could influence its existing investment narrative around digitization and market expansion.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Intercontinental Exchange Investment Narrative Recap

To own ICE, you need to believe in its role as a core market infrastructure provider, benefiting from ongoing digitization, data demand, and derivative market depth. The recent GPU compute futures plans, ERCOT margining expansion, and crypto-linked oil perps look additive but do not obviously change the near term focus on integrating Black Knight or the key risk that new technologies and low cost venues could pressure traditional exchange and data economics.

Among the latest announcements, the expansion of ICE’s IRM 2 VaR based margining to ERCOT power markets ties most directly into the existing catalyst of deeper energy and environmental derivatives penetration. It reinforces ICE’s effort to provide more sophisticated risk tools around its largest energy contracts, which sit at the heart of the volume and data growth narrative that many investors already focus on when assessing the business.

However, investors should be aware that rising technology spend and emerging competitors in AI, cloud, and DeFi could eventually challenge ICE’s traditional infrastructure if ...

Intercontinental Exchange's narrative projects $12.3 billion revenue and $4.5 billion earnings by 2029. This requires 5.7% yearly revenue growth and an earnings increase of about $0.6 billion from $3.9 billion today.

Uncover how Intercontinental Exchange's forecasts yield a $200.67 fair value, a 31% upside to its current price.

Exploring Other Perspectives

ICE 1-Year Stock Price Chart
ICE 1-Year Stock Price Chart

Five members of the Simply Wall St Community currently place ICE’s fair value between US$140 and US$200.67, highlighting a wide spread of opinions. You should weigh that diversity against how much confidence you have in ICE’s push to extend risk tools like IRM 2 across energy and newer asset classes, and consider how different outcomes there could shape the company’s long term earnings power.

Explore 5 other fair value estimates on Intercontinental Exchange - why the stock might be worth as much as 31% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Intercontinental Exchange research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
  • Our free Intercontinental Exchange research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intercontinental Exchange's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

  • Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
  • Find 49 companies with promising cash flow potential yet trading below their fair value.
  • AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.